Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced the establishment of an independent service unit named formycon. formycon offers services for external customers focusing on formulation development, drug product manufacturing and process development, as well as quality control and analytics. Scil Technology’s long-standing track record in protein development enables formycon to support its customers with key activities such as protein characterization, preformulation, formulation development and drug product production as well as analytics under GMP and non-GMP conditions (including analytical method development).
In addition to liquid and freeze dried formulations, formycon also offers liposomal and specialty formulations, e.g. for topical and local administration – an area which distinguishes formycon from most other service providers worldwide. Therefore, formycon´s core strengths lie in the combination of a broad range of formulation types with comprehensive knowledge of regulatory processes and excellent analytics according to GMP standards and the requirements outlined by the ICH and pharmacopoeias.
formycon is operating on a fee for service basis and employs a staff of 20. The unit is licensed and GMP-certified as an analytical laboratory.